MINNEAPOLIS--(BUSINESS WIRE)--March 20, 2006--MGI PHARMA, INC. (Nasdaq:MOGN), an oncology- and acute care- focused biopharmaceutical company, today announced the initiation of the Aquavan(R) (fospropofol disodium) Injection pivotal program. This program consists of two randomized, double blind, multicenter phase 3 trials and an open label safety study.
